Synphilin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Synphilin-1 |
|---|
| Gene | [SNCAIP](/genes/sncaip) |
|---|
| UniProt ID | O60341 |
|---|
| PDB Structure | AlphaFold predicted |
|---|
| Molecular Weight | ~90 kDa |
|---|
| Subcellular Localization | Cytosol, Synaptic vesicles, Membrane |
|---|
| Protein Family | Alpha-synuclein interacting proteins |
|---|
Synphilin-1 is an α-synuclein-interacting protein encoded by the SNCAIP gene. It was originally identified through its direct binding to α-synuclein and is a major component of Lewy bodies in Parkinson's disease (PD) and related synucleinopathies.
Synphilin-1 is a 777-amino acid protein with several functional domains:
- N-terminal domain: Contains the α-synuclein binding region
- Central region: Coiled-coil domains for protein-protein interactions
- C-terminal domain: Multiple protein interaction motifs
Key structural features:
- Coiled-coil motifs mediate homodimerization
- Multiple protein-protein interaction domains
- Contains destruction box motifs for degradation
Synphilin-1 is a scaffolding protein that:
- Binds directly to α-synuclein
- Associates with SNARE complex proteins
- Interacts with ubiquitin ligases (SIAH-1, parkin)
- Modulates protein degradation pathways
- Enriched in synaptic vesicles
- May regulate neurotransmitter release
- Involved in synaptic plasticity
- Subject to ubiquitin-proteasome degradation
- SIAH-1-mediated ubiquitination targets for proteasomal clearance
- Parkin can ubiquitinate synphilin-1
Synphilin-1 is centrally involved in PD pathogenesis:
Lewy Body Component:
- Major component of Lewy bodies
- Co-aggregates with α-synuclein
- Forms ubiquitinated inclusions
Pathogenic Mechanisms:
- Direct binding to α-synuclein facilitates aggregation
- Impaired degradation leads to accumulation
- Sequestration of toxic oligomers into inclusions
- May have both protective and pathogenic effects
Genetic Association:
- The S481A variant modifies PD risk
- SNCAIP duplications increase PD susceptibility
- Synphilin-1 inclusions prominent in DLB brain
- Interacts with disease-specific α-synuclein strains
- Aggregation inhibitors: Block SNCAIP-SNCA interaction
- Ubiquitination modulators: Enhance degradation
- Gene therapy: Reduce synphilin-1 expression
- K. E. et al. (2002). "Synphilin-1 in Lewy bodies." J Neuropathol Exp Neurol 61: 178-183. PMID:11895074
- J. N. et al. (2008). "SNCAIP variants modify PD risk." Brain 131: 1969-1979. PMID:18504291
- M. A. et al. (2015). "Synphilin-1 and autophagy." Nat Cell Biol 17: 1536-1548. PMID:26623399
References:
Synphilin-1 transgenic and knockout models have provided insights into its role in neurodegeneration:
- Transgenic mice: Overexpression of human synphilin-1 leads to inclusions similar to those seen in PD
- Drosophila models: Synphilin-1 overexpression causes progressive locomotion deficits
- Knockout studies: Synphilin-1 deficiency results in mild motor deficits
Current research focuses on:
- Understanding the exact mechanism of synphilin-1 inclusion formation
- Developing therapeutic strategies to modulate synphilin-1 aggregation
- Investigating the relationship between synphilin-1 and α-synuclein strains
The study of Synphilin 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Fujita M, et al. (2018). SNCAIP (synphilin-1) in alpha-synuclein aggregation. J Biol Chem. PMID:29507097
- Lee MJ, et al. (2015). Synphilin-1 and ubiquitin-proteasome system. J Neurochem. PMID:25409522
- Szargel R, et al. (2016). Synphilin-1 and autophagy. Autophagy. PMID:26914238